EyeGene Inc (185490) — Cash Flow-to-Debt Ratio
EyeGene Inc (185490) has a Cash Flow-to-Debt Ratio of -0.07x as of September 2025, meaning its operating cash flow of ₩-904.39 Million could theoretically repay 0% of its total liabilities (₩12.55 Billion) in one year. See 185490 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
EyeGene Inc Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for EyeGene Inc across 11 annual periods. Also explore EyeGene Inc annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for EyeGene Inc (2014–2024)
Year-by-year debt coverage analysis for EyeGene Inc. For market capitalisation and broader financial context, see 185490 company net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.81x | ₩-12.17 Billion | ₩14.98 Billion | ▲ +44.3% |
| 2023 | -1.46x | ₩-20.07 Billion | ₩13.77 Billion | ▼ -7.2% |
| 2022 | -1.36x | ₩-18.57 Billion | ₩13.65 Billion | ▲ +27.4% |
| 2021 | -1.87x | ₩-30.00 Billion | ₩16.02 Billion | ▼ -505.3% |
| 2020 | -0.31x | ₩-9.75 Billion | ₩31.53 Billion | ▼ -5.1% |
| 2019 | -0.29x | ₩-8.32 Billion | ₩28.28 Billion | ▼ -20.7% |
| 2018 | -0.24x | ₩-7.48 Billion | ₩30.70 Billion | ▲ +76.5% |
| 2017 | -1.03x | ₩-6.76 Billion | ₩6.53 Billion | ▲ +59.0% |
| 2016 | -2.52x | ₩-5.99 Billion | ₩2.37 Billion | ▲ +11.8% |
| 2015 | -2.86x | ₩-4.48 Billion | ₩1.57 Billion | ▼ -102.1% |
| 2014 | -1.42x | ₩-2.39 Billion | ₩1.69 Billion | — |